Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to Post FY2022 Earnings of ($9.22) Per Share, Jefferies Financial Group Forecasts
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to Post FY2022 Earnings of ($9.22) Per Share, Jefferies Financial Group Forecasts
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) – Research analysts at Jefferies Financial Group upped their FY2022 earnings per share estimates for Ultragenyx Pharmaceutical in a research note issued on Wednesday, February 1st. Jefferies Financial Group analyst M. Raycroft now anticipates that the biopharmaceutical company will earn ($9.22) per share for the year, up from their prior estimate of ($9.25). The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($8.84) per share. Jefferies Financial Group also issued estimates for Ultragenyx Pharmaceutical's Q4 2022 earnings at ($2.25) EPS, Q1 2023 earnings at ($1.45) EPS, Q2 2023 earnings at ($1.41) EPS, Q3 2023 earnings at ($1.45) EPS, FY2023 earnings at ($5.64) EPS, FY2024 earnings at ($4.59) EPS, FY2025 earnings at ($5.19) EPS, FY2026 earnings at $0.35 EPS and FY2027 earnings at $12.32 EPS.
Ultragenyx製藥公司(納斯達克：Rare-Get Rating)-傑富瑞金融集團的研究分析師在2月1日星期三發佈的一份研究報告中上調了對Ultragenyx製藥公司2022財年每股收益的預期。傑富瑞金融集團(Jefferies Financial Group)分析師M.Raycroft現在預計，這家生物製藥公司今年的每股收益將達到9.22美元，高於此前預測的9.25美元。對Ultragenyx製藥公司目前全年收益的普遍估計是每股8.84美元。傑富瑞金融集團還發布了對Ultragenyx製藥公司2022年第四季度每股收益(2.25美元)、2023年第一季度每股收益(1.45美元)、2023年第二季度每股收益(1.41美元)、2023年第三季度每股收益(1.45美元)、2023財年每股收益(5.64美元)、2024財年每股收益(4.59美元)、2025財年每股收益(5.19美元)、2026財年每股收益0.35美元和2027財年每股收益12.32美元的預期。
A number of other research analysts also recently issued reports on RARE. Cowen lowered their price target on Ultragenyx Pharmaceutical from $86.00 to $65.00 in a report on Thursday, November 3rd. Credit Suisse Group lowered their price target on Ultragenyx Pharmaceutical from $105.00 to $96.00 and set an "outperform" rating on the stock in a report on Thursday, November 3rd. Morgan Stanley lowered their price target on Ultragenyx Pharmaceutical from $100.00 to $95.00 and set an "overweight" rating on the stock in a report on Friday. SVB Leerink lowered their price target on Ultragenyx Pharmaceutical from $115.00 to $108.00 and set an "outperform" rating on the stock in a report on Thursday, November 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $82.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, December 30th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $91.69.
其他一些研究分析師最近也發佈了關於REARE的報告。考恩在11月3日星期四的一份報告中將他們對Ultragenyx製藥公司的目標價從86.00美元下調至65.00美元。瑞士信貸集團在11月3日週四的一份報告中將Ultragenyx Pharmtics的目標價從105.00美元下調至96美元，並對該股設定了“跑贏大盤”的評級。摩根士丹利在週五的一份報告中將他們對Ultragenyx Pharmtics的目標價從100.00美元下調至95美元，並對該股設定了“增持”評級。SVB Leerink在11月3日週四的一份報告中將他們對Ultragenyx Pharmtics的目標價從115.00美元下調至108.00美元，並對該股設定了“跑贏大盤”的評級。最後，在12月30日星期五的一份報告中，HC Wainwright重申了買入評級，併為Ultragenyx製藥公司的股票設定了82.00美元的目標價。三位分析師對該股的評級為持有，十位分析師對該公司的評級為買入。根據MarketBeat.com的數據，該公司的普遍評級為“適度買入”，平均目標價為91.69美元。
Ultragenyx Pharmaceutical Trading Down 3.4 %
Ultragenyx製藥公司股價下跌3.4%
Institutional Trading of Ultragenyx Pharmaceutical
Ultragenyx製藥公司的制度性交易
Several institutional investors have recently made changes to their positions in RARE. RTW Investments LP grew its position in shares of Ultragenyx Pharmaceutical by 71.9% during the third quarter. RTW Investments LP now owns 2,359,996 shares of the biopharmaceutical company's stock worth $97,727,000 after purchasing an additional 986,712 shares in the last quarter. State Street Corp grew its holdings in Ultragenyx Pharmaceutical by 26.1% during the 2nd quarter. State Street Corp now owns 2,457,308 shares of the biopharmaceutical company's stock valued at $146,603,000 after buying an additional 508,624 shares in the last quarter. Wellington Management Group LLP grew its holdings in Ultragenyx Pharmaceutical by 17.1% during the 1st quarter. Wellington Management Group LLP now owns 3,370,245 shares of the biopharmaceutical company's stock valued at $244,747,000 after buying an additional 492,842 shares in the last quarter. BlackRock Inc. grew its holdings in Ultragenyx Pharmaceutical by 9.2% during the 3rd quarter. BlackRock Inc. now owns 3,927,639 shares of the biopharmaceutical company's stock valued at $162,645,000 after buying an additional 330,055 shares in the last quarter. Finally, Eventide Asset Management LLC purchased a new position in Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $12,663,000. Hedge funds and other institutional investors own 93.17% of the company's stock.
幾家機構投資者最近改變了他們在Rare的頭寸。RTW Investments LP在第三季度將其在Ultragenyx製藥公司的股票頭寸增加了71.9%。RTW Investments LP現在擁有這家生物製藥公司2,359,996股票，價值97,727,000美元，上個季度又購買了986,712股票。道富集團在第二季度增持了26.1%的Ultragenyx Pharmtics股份。道富集團目前持有這家生物製藥公司2,457,308股股票，價值146,603,000美元，上一季度又購買了508,624股。惠靈頓管理集團有限責任公司在第一季度增持了17.1%的Ultragenyx製藥股份。惠靈頓管理集團(Wellington Management Group LLP)現在擁有這家生物製藥公司3370,245股股票，價值244,747,000美元，上個季度又購買了492,842股。貝萊德股份有限公司在第三季度增持了Ultragenyx製藥9.2%的股份。貝萊德股份有限公司現在持有這家生物製藥公司3,927,639股股票，價值162,645,000美元，上個季度又購買了330,055股。最後，Evende Asset Management LLC在第三季度購買了Ultragenyx製藥公司的一個新頭寸，價值約為12,663,000美元。對衝基金和其他機構投資者持有該公司93.17%的股票。
Insider Transactions at Ultragenyx Pharmaceutical
Ultragenyx製藥公司的內幕交易
In other news, CAO Theodore Alan Huizenga sold 2,031 shares of the firm's stock in a transaction dated Wednesday, December 21st. The stock was sold at an average price of $43.96, for a total value of $89,282.76. Following the transaction, the chief accounting officer now owns 16,197 shares of the company's stock, valued at $712,020.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 6.70% of the company's stock.
在其他新聞方面，首席財務官西奧多·艾倫·惠曾加在12月21日星期三的一筆交易中出售了2031股該公司的股票。這隻股票的平均售價為43.96美元，總價值為89,282.76美元。交易完成後，這位首席會計官現在持有該公司16,197股股票，價值712,020.12美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可以通過這個環節。公司內部人士持有該公司6.70%的股份。
Ultragenyx Pharmaceutical Company Profile
Ultragenyx製藥公司簡介
(Get Rating)
(獲取評級)
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII.
Ultragenyx製藥公司是一家生物製藥公司，從事治療嚴重罕見和超罕見遺傳病的新產品的識別、收購、開發和商業化。其產品包括Mepsevii和Crysvita。Mepsevii是一種靜脈酶替代療法，用於治療粘多糖病VII。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- 免費獲取StockNews.com關於Ultragenyx製藥公司的研究報告(Rare)
- 市場回顧周-1/30-2/3
- 細價股值得嗎？你應該投資細價股嗎？
- Zimmer Biomet盈利節節攀升，增長可能被計入價格
- 人工智能軟件製造商EPAM號稱科技板塊漲幅最大
- 福特股票在盈利大幅下滑後繼續前進
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Ultragenyx藥學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Ultragenyx製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。